Ownership Summary
Recent 13F filings as of September 2025 show that 2 institutional investors hold a position in Lyell Immunopharma, Inc. (NASDAQ:LYEL).
- The percentage of Lyell Immunopharma owned by institutions changed from 17.9% in June 2025 to 3.6% in September 2025, marking a slight down trend.
- Quarterly data indicates a 2.16% shift in institutional share volume, and the annual owner count reflects a decrease of 98.29%.
- A review of institutional activity for Lyell Immunopharma shows 1 of 2 filers increasing their positions, while 0 reduced their stake, and 1 remained unchanged.
- Collectively, institutional investors increased their stake in Lyell Immunopharma to 650.35K shares as of September 2025, a change that is up by 13.72K shares quarter on quarter and down 5.76Mn shares year over year.
- With 595.47K shares, Decheng Capital LLC commands the largest institutional position in Lyell Immunopharma as of September 30, 2025, equating to 3.27% of the company.
- Among the most significant buyers of Lyell Immunopharma during September 2025 were TAKEDA PHARMACEUTICAL CO LTD (13.72K).
- The top 2 institutional holders of Lyell Immunopharma for the quarter ending September 2025 included Decheng Capital LLC (595.47K), TAKEDA PHARMACEUTICAL CO LTD (54.89K).